These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27838121)

  • 41. Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease.
    Rasalingam R; Boden WE
    Am J Cardiol; 2019 May; 123(10):1729-1731. PubMed ID: 30922541
    [No Abstract]   [Full Text] [Related]  

  • 42. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
    Wenger NK; Chaitman B; Vetrovec GW
    Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ranolazine in the prevention and treatment of atrial fibrillation: A protocol for meta-analysis.
    Yuan C; Luo W; Ren X; Ya M; Yan W; Hui Q
    Medicine (Baltimore); 2021 Apr; 100(16):e25437. PubMed ID: 33879675
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ranolazine: focusing on angina pectoris.
    McCullough PA
    Drugs Today (Barc); 2006 Mar; 42(3):177-83. PubMed ID: 16628259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perspective: does ranolazine have potential for the treatment of atrial fibrillation?
    Hancox JC; Doggrell SA
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1465-74. PubMed ID: 21105855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of ranolazine in heart failure: From cellular to clinic perspective.
    Kaplan A; Amin G; Abidi E; Altara R; Booz GW; Zouein FA
    Eur J Pharmacol; 2022 Mar; 919():174787. PubMed ID: 35114190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris.
    Fanaroff AC; Prather K; Brucker A; Wojdyla D; Davidson-Ray L; Mark DB; Williams RB; Barefoot J; Weisz G; Ben-Yehuda O; Stone GW; Ohman EM; Alexander KP
    Am J Cardiol; 2019 May; 123(9):1399-1405. PubMed ID: 30771861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ranolazine for Symptomatic Management of Microvascular Angina.
    Rayner-Hartley E; Parvand M; Humphries KH; Starovoytov A; Park JE; Sedlak T
    Am J Ther; 2020; 27(2):e151-e158. PubMed ID: 29746286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population.
    Borzi M; Intorcia A; Perrone MA; Grilli G; Sergi D; Borzi M; Romeo F
    J Cardiovasc Med (Hagerstown); 2018 Apr; 19(4):186-190. PubMed ID: 29432398
    [No Abstract]   [Full Text] [Related]  

  • 53. Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?
    Mezincescu A; Karthikeyan VJ; Nadar SK
    Sultan Qaboos Univ Med J; 2018 Feb; 18(1):e13-e23. PubMed ID: 29666676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
    Ambrosio G; Tamargo J; Grant PJ
    Diab Vasc Dis Res; 2016 Mar; 13(2):98-112. PubMed ID: 26873904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
    Rehberger-Likozar A; Šebeštjen M
    Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.
    Hammond DA; Smotherman C; Jankowski CA; Tan S; Osian O; Kraemer D; DeLosSantos M
    Clin Res Cardiol; 2015 May; 104(5):410-7. PubMed ID: 25416563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ranolazine for chronic stable angina.
    Nash DT; Nash SD
    Lancet; 2008 Oct; 372(9646):1335-41. PubMed ID: 18929905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ranolazine: new drug. Stable angina: not worth the risk.
    Prescrire Int; 2009 Aug; 18(102):148-7. PubMed ID: 19743543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New oral nitric oxide-dependent medications for patients with coronary artery disease who have persistent angina pectoris.
    Blum A
    Coron Artery Dis; 2015 Dec; 26(8):639-41. PubMed ID: 26528628
    [No Abstract]   [Full Text] [Related]  

  • 60. Emerging clinical role of ranolazine in the management of angina.
    Vadnais DS; Wenger NK
    Ther Clin Risk Manag; 2010 Oct; 6():517-30. PubMed ID: 21063462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.